Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention

High aggregatory responses despite antiplatelet treatment is associated with an increased risk of thrombotic complications following percutaneous coronary intervention (PCI). In the present study, we investigated the relationship between platelet aggregatory responses to ADP and the release of CD40L (sCD40L): an immunomodulatory compound involved in atherothrombosis – in patients undergoing PCI. ADP-induced platelet aggregation, sCD40L and soluble P-selectin (sP-selectin) were determined before and 24 h after PCI, in samples from 52 patients receiving aspirin and thienopyridines. Platelet aggregation to ADP above the median was defined as ‘high aggregation’, and aggregation below the median as ‘low aggregation’. Data below are medians and interquartile ranges. Patients with ‘high platelet aggregability’ had a significantly higher increase in both sCD40L (Δ-values: 0.78 (−0.19–3.18) vs. −0.65 (−2.10–0.00) ng/ml, P = 0.002) and sP-selectin (Δ-values: 8.0 (−2.00–16.00) vs. 4.50 (−13.00–0.50) ng/ml, P = 0.001) compared with patients with ‘low platelet aggregability’. In a multivariate linear regression analysis adjusted for clinical characteristics and type of preintervention therapy, the only independent predictors of sCD40L and sP-selectin were platelet aggregation to ADP before PCI (P < 0.001) and the combination of platelet aggregation to ADP before PCI and urgency of PCI (P < 0.001). Circulating CD40L is more markedly increased after PCI in patients with high ADP-induced platelet aggregation.

[1]  J. Ribeiro,et al.  Coronary stent implantation may seal the inflammatory response in patients with acute coronary syndromes. , 2008, International journal of cardiology.

[2]  F. Santilli,et al.  CD40/CD40L system and vascular disease , 2007, Internal and emergency medicine.

[3]  A. Maree,et al.  Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease , 2007, Circulation.

[4]  M. Grabowski,et al.  Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects , 2007, Journal of Thrombosis and Thrombolysis.

[5]  G. Ma,et al.  Relationship between upregulation of CD40 system and restenosis in patients after percutaneous coronary intervention , 2007, Acta Pharmacologica Sinica.

[6]  R. Ferrari,et al.  Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. , 2006, Journal of the American College of Cardiology.

[7]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[8]  G. Montalescot,et al.  A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. , 2006, Journal of the American College of Cardiology.

[9]  G. Ma,et al.  The clinical implications of increased coexpression of CD40-CD40 ligand system and C-reactive protein in patients after percutaneous coronary intervention. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[10]  Cheuk-Kwan Sun,et al.  Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. , 2006, The American journal of cardiology.

[11]  N. Barış,et al.  Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. , 2006, The American journal of cardiology.

[12]  P. Gurbel,et al.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. , 2005, Journal of the American College of Cardiology.

[13]  F. Verheugt,et al.  ESC guidelines for percutaneous coronary interventions. , 2005, European heart journal.

[14]  V. Pasceri,et al.  Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study* , 2005, Circulation.

[15]  Antonio Colombo,et al.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. , 2005, European heart journal.

[16]  Deepak L. Bhatt,et al.  Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.

[17]  E. Salamé,et al.  Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. , 2005, The American journal of cardiology.

[18]  H. Hod,et al.  Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.

[19]  F. Cipollone,et al.  Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty , 2003, Circulation.

[20]  Gregory Y H Lip,et al.  The adhesion molecule P-selectin and cardiovascular disease. , 2003, European heart journal.

[21]  R. Callard,et al.  CD40 Is Constitutively Expressed on Platelets and Provides a Novel Mechanism for Platelet Activation , 2003, Circulation research.

[22]  P. Thiagarajan,et al.  P-Selectin Expression on Platelets Determines Size and Stability of Platelet Aggregates , 2000, Circulation.

[23]  A. Siegbahn,et al.  Role of Platelet P-Selectin and CD40 Ligand in the Induction of Monocytic Tissue Factor Expression , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[24]  E. Braunwald,et al.  A classification of unstable angina revisited. , 2000, Circulation.

[25]  M. Goldman,et al.  CD40 Engagement on Endothelial Cells Promotes Tissue Factor-dependent Procoagulant Activity , 1998, Thrombosis and Haemostasis.

[26]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[27]  G. Pellegrini,et al.  P-selectin induces the expression of tissue factor on monocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Quon,et al.  The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. , 2007, Atherosclerosis.

[29]  P. Libby,et al.  CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. , 2000, The American journal of pathology.